Jeffrey Madden

ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s Disease. The Company’s lead compound AD04™ is a subcutaneous injectable therapy that entered, in November 2023, confirmatory Phase 2b clinical trials in Europe, to evaluate its safety and efficacy in early AD patients. The Company believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to attack the misfolded proteins, beta amyloid and tau. The Company is exploring additional approaches to mitigating neurodegenerative disease, among them increasing the levels of Klotho, a life and health extending protein which will have an overall impact on longevity.

Klothea Bio is a preclinical biotechnology company developing next-generation longevity therapeutics aimed at delaying age-related diseases. Its lead program uses a proprietary mRNA platform to boost endogenous secretion of soluble Klotho—a pleiotropic protein with potential benefits across multiple organ systems, including the brain, heart, kidneys, lungs, and bones. By restoring Klotho levels diminished by aging, disease, or genetics, Klothea aims to unlock a new therapeutic pathway for enhancing health span. The company is targeting Phase 1 clinical trials in early 2026, with metabolic syndrome as the first planned indication. Klothea is proud to partner with Healthy Longevity Clinic that has been chosen as a semifinalist in the $101 million XPRIZE Healthspan competition for its approach to increase healthspan with our proprietary klotho mRNA therapy.